Abstract
Twenty-three patients with advanced renal cell cancer were treated with Didemnin B. One partial response was achieved (5%) in 21 evaluable patients. An allergic reaction was noted in four patients including one patient with anaphylaxis. Didemnin B is not recommended in the treatment of renal cell carcinoma.
Publication types
-
Clinical Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Aged
-
Antibiotics, Antineoplastic / administration & dosage
-
Antibiotics, Antineoplastic / adverse effects
-
Antibiotics, Antineoplastic / therapeutic use*
-
Carcinoma, Renal Cell / drug therapy*
-
Depsipeptides*
-
Drug Evaluation
-
Drugs, Investigational / administration & dosage
-
Drugs, Investigational / adverse effects
-
Drugs, Investigational / therapeutic use*
-
Female
-
Humans
-
Kidney Neoplasms / drug therapy*
-
Male
-
Middle Aged
-
Peptides, Cyclic / administration & dosage
-
Peptides, Cyclic / adverse effects
-
Peptides, Cyclic / therapeutic use*
Substances
-
Antibiotics, Antineoplastic
-
Depsipeptides
-
Drugs, Investigational
-
Peptides, Cyclic
-
didemnins